Description

According to a report by StrategyHelix, the global transcatheter treatment device market is set to increase by US$ 11.6 billion during 2022-2028, growing at a CAGR of 14.3% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for transcatheter treatment device. The global transcatheter treatment device market is segmented on the basis of product, procedure approach, valve type, and region. On the basis of product, the global transcatheter treatment device market has been segmented into transcatheter aortic valve repair and replacement devices (TAVR/TAVI), transcatheter mitral valve repair (TMVR) devices, transcatheter tricuspid valve repair (TTVR) devices. The transcatheter aortic valve repair and replacement devices (TAVR/TAVI) segment is estimated to account for the largest share of the global transcatheter treatment device market. By procedure approach, the global transcatheter treatment device market has been segmented into transfemoral, transapical, transaortic. The transfemoral segment held the largest revenue share in 2021. Based on valve type, the global transcatheter treatment device market is categorized into balloon-expanded valves, self-expanded valves. Globally, the self-expanded valves segment made up the largest share of the transcatheter treatment device market. Geographically, the global transcatheter treatment device market is segmented into Asia Pacific, Europe, North America, Rest of the World (RoW). North America was the largest contributor to the global transcatheter treatment device market in 2021.

The global transcatheter treatment device market is highly competitive. The report also includes the profiles of leading companies such as Abbott Laboratories, Biosensors International Group Ltd., Biotronik SE & Co. KG., Boston Scientific Corporation, Bracco S.p.A., Edwards Lifesciences Corporation, Medtronic plc, Neovasc Inc. Competitive landscape gives a description of the competitive nature of the global transcatheter treatment device market and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the transcatheter treatment device market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: transcatheter aortic valve repair and replacement devices (TAVR/TAVI), transcatheter mitral valve repair (TMVR) devices, transcatheter tricuspid valve repair (TTVR) devices
Procedure approach: transfemoral, transapical, transaortic
Valve type: balloon-expanded valves, self-expanded valves
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028
Company mentioned: Abbott Laboratories, Biosensors International Group Ltd., Biotronik SE & Co. KG., Boston Scientific Corporation, Bracco S.p.A., Edwards Lifesciences Corporation, Medtronic plc, Neovasc Inc.

Key Benefits for Stakeholders

– Get a comprehensive picture of the global transcatheter treatment device market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Transcatheter treatment device market overview
Part 3. Market breakdown by product
– Transcatheter aortic valve repair and replacement devices (TAVR/TAVI)
– Transcatheter mitral valve repair (TMVR) devices
– Transcatheter tricuspid valve repair (TTVR) devices
Part 4. Market breakdown by procedure approach
– Transfemoral
– Transapical
– Transaortic
Part 5. Market breakdown by valve type
– Balloon-expanded valves
– Self-expanded valves
Part 6. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 7. Key companies
– Abbott Laboratories
– Biosensors International Group, Ltd.
– Biotronik SE & Co. KG.
– Boston Scientific Corporation
– Bracco S.p.A.
– Edwards Lifesciences Corporation
– Medtronic plc
– Neovasc Inc.
About StrategyHelix
Disclaimer